Tandem Diabetes Care (TNDM) AI Stock Analysis

• Market Cap: $1.54B
• Dividend Yield: N/A
• Average Volume (3M): 1.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: 17.87%
• EPS Growth: -57.03%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.31
• Shares Outstanding: 67,802,360
• 10 Day Avg. Volume: 752,985
• 30 Day Avg. Volume: 1,350,954
• PEG Ratio: 0.43
• Price to Book (P/B): 8.96
• Price to Sales (P/S): 2.51
• P/FCF Ratio: 472.08
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 0.94
• Enterprise Value/Gross Profit: 1.78
• Enterprise Value/Ebitda: -5.29
• 1Y Price Target: $26.33
• Price Target Upside: 17.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 18
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $22.00 ▼(-2.22% Downside)

Tandem Diabetes Care's overall stock score reflects a mix of financial challenges and positive strategic developments. The financial performance is a significant concern due to declining revenue and high leverage. However, strong technical indicators and positive earnings call sentiment provide a more optimistic outlook. The recent board appointment further supports the company's strategic direction.

Positive Factors

Product Innovation

The integration with Abbott's FreeStyle Libre 3 Plus enhances product offerings, potentially increasing market share and customer satisfaction.

Pharmacy Channel Expansion

Expanding pharmacy access can drive sales growth and improve customer access, supporting long-term revenue stability.

Board Appointment

The addition of a seasoned finance executive to the board strengthens governance and strategic direction, aiding long-term growth.

Negative Factors

High Leverage

High leverage can constrain financial flexibility and increase risk, potentially impacting future investment and growth opportunities.

Revenue Decline

Decreasing revenue growth suggests challenges in market competitiveness and product demand, affecting long-term profitability.

Profitability Challenges

Ongoing profitability issues indicate cost management challenges, which could hinder financial health and operational efficiency.

Tandem Diabetes Care Business Overview & Revenue Model

Company Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

How the Company Makes Money

Tandem Diabetes Care generates revenue primarily through the sale of its insulin delivery devices, including the t:slim X2 insulin pump and associated supplies such as infusion sets and cartridges. The company operates on a direct sales model, selling products to healthcare providers, diabetes clinics, and directly to consumers. Additionally, Tandem benefits from partnerships with insulin manufacturers and healthcare systems that facilitate the integration of its products with other diabetes management solutions. Revenue is also supported by reimbursement from insurance companies, which cover a portion of the costs for patients using Tandem's devices. Furthermore, the company's ongoing innovation and product development efforts allow it to maintain a competitive edge, potentially leading to increased sales and market share.

Tandem Diabetes Care Financial Statement Overview

Summary

Tandem Diabetes Care is facing significant financial challenges, with declining revenue growth and profitability issues. The high leverage and negative return on equity indicate financial risk, while the cash flow position shows some improvement. The company needs to focus on revenue growth, cost management, and debt reduction to enhance its financial performance and stability.

Income Statement

Tandem Diabetes Care has experienced a decline in revenue growth, with a negative growth rate of -10.17% in the TTM period. The company is facing profitability challenges, as indicated by negative net profit and EBIT margins. However, the gross profit margin remains relatively stable at 53.23%, suggesting some operational efficiency. The company needs to address its declining revenue and improve its cost management to enhance profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 3.38 in the TTM period, indicating significant leverage and potential financial risk. The return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is low, suggesting limited financial stability. Tandem Diabetes Care should focus on reducing its debt levels and improving its equity position to strengthen its financial health.

Cash Flow

The cash flow statement shows a positive free cash flow growth rate of 32.07% in the TTM period, indicating improved cash generation. However, the operating cash flow to net income ratio is negative, highlighting challenges in converting income into cash. The free cash flow to net income ratio is high, suggesting that the company is generating cash despite net losses. Tandem Diabetes Care should focus on enhancing its operational cash flow to support its financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.01B	940.20M	747.72M	801.22M	702.80M	498.83M
Gross Profit	536.01M	489.57M	367.69M	412.99M	376.21M	260.52M
EBITDA	-179.70M	-99.13M	-196.46M	-74.21M	34.06M	-13.03M
Net Income	-203.37M	-96.03M	-222.61M	-94.59M	15.57M	-34.38M
Balance Sheet
Total Assets	874.65M	967.66M	952.66M	1.05B	905.14M	716.41M
Cash, Cash Equivalents and Short-Term Investments	319.11M	438.33M	467.91M	616.90M	623.81M	484.94M
Total Debt	449.28M	473.56M	415.67M	419.88M	314.67M	228.32M
Total Liabilities	741.69M	704.56M	639.03M	612.84M	472.02M	350.11M
Stockholders Equity	132.97M	263.10M	313.63M	439.95M	433.11M	366.31M
Cash Flow
Free Cash Flow	-25.13M	4.99M	-58.61M	16.37M	87.85M	-7.63M
Operating Cash Flow	-8.79M	24.23M	-31.81M	50.46M	111.36M	24.67M
Investing Cash Flow	92.86M	-23.48M	-85.74M	33.17M	-186.88M	-296.06M
Financing Cash Flow	-43.67M	8.37M	4.11M	16.88M	51.93M	314.44M

Tandem Diabetes Care Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNDM, the sentiment is Positive. The current price of 22.5 is above the 20-day moving average (MA) of 22.29, above the 50-day MA of 19.82, and above the 200-day MA of 17.30, indicating a bullish trend. The MACD of 0.77 indicates Positive momentum. The RSI at 56.32 is Neutral, neither overbought nor oversold. The STOCH value of 60.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNDM.

Tandem Diabetes Care Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	$127.91B	26.66	9.81%	2.76%	5.34%	13.15%
DXCM	79 Outperform	$27.34B	38.09	30.63%	―	14.21%	5.66%
EW	79 Outperform	$49.82B	36.11	13.59%	―	0.19%	65.58%
PODD	70 Outperform	$21.05B	84.98	19.68%	―	27.12%	-41.72%
TNDM	61 Neutral	$1.54B	-7.38	-109.73%	―	17.87%	-57.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$27.56B	-36.05	―	3.30%	-0.76%	-55.03%

Tandem Diabetes Care Corporate Events

Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules

On December 26, 2025, Tandem Diabetes Care’s board of directors approved Amended and Restated Bylaws as part of a periodic governance review, immediately replacing the prior bylaws. The revisions significantly update advance notice requirements for shareholder director nominations and other proposals, tightening disclosure obligations, limiting the number of nominees to the seats up for election, restricting substitute nominees, and enabling the company to disregard nominations if shareholders fail to comply with federal proxy rules or do not appear to present their nominees. Additional changes formalize the board’s authority to cancel, reschedule or postpone shareholder meetings, reserve the white proxy card exclusively for the board, modernize indemnification and notice provisions in line with Delaware corporate law, simplify and clarify voting standards for director elections, and remove the requirement to provide a physical shareholder list at meetings. Collectively, these amendments streamline corporate governance, reinforce the board’s control over the shareholder meeting and proxy process, and may shape how activist investors and other shareholders engage with the company in future contested or routine elections.

The most recent analyst rating on (TNDM) stock is a Hold with a $24.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.

Tandem Diabetes Care Appoints Sandra Beaver to Board

On November 7, 2025, Tandem Diabetes Care appointed Sandra Beaver to its Board of Directors, expanding the board from eight to nine members. Ms. Beaver, a seasoned finance executive with over 20 years of experience, will serve on the Audit Committee and the Cybersecurity and Data Privacy Committee. Her appointment is expected to support Tandem’s growth strategy as it continues to innovate in digital health solutions and expand into new markets.

The most recent analyst rating on (TNDM) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.